8-K Announcements
1Material company update
Sep 12, 2023·SEC
Abrdn Healthcare Investors(HQH)Earnings, Financials & Key Ratios
HQH•NYSE
$22.00
6.2× P/E·Price updated Jul 6, 2026
AboutAbrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.Show more
- EBITDA$0
- Net Income$185M+228.3%
- EPS (Diluted)3.55+211.4%
- Gross Margin100%
- Operating Margin-2.05%+82.2%
- Net Margin1717.36%+213.7%
- ROE18.58%+204.7%
HQH Price & Volume
Abrdn Healthcare Investors (HQH) stock price & volume — 10-year historical chart
Loading chart...
Volatile Biotech Gains Mask Structural Income Deficits
Investment Thesis • Updated 2024Q4
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Adequate
Cash Flow:Mixed
Primary Risk:Biotech Innovation Cycle Volatility
Key Thesis Takeaways
- Abrdn Healthcare Investors functions as a pure-play investment vehicle heavily exposed to the cyclical volatility of the biotechnology sector, where net income is driven by mark-to-market asset valuations rather than recurring revenue.
- While the fund has successfully deleveraged to zero total debt as of 2024Q4, the persistent reliance on unrealized gains to cover operational expenses and dividend distributions creates significant long-term sustainability risks.
- Investors should monitor the fund's ability to bridge the gap between its $85.2 million in 2024Q4 net income and its limited $5.5 million in quarterly investment revenue.
Verdict Logic
while the fund maintains a clean balance sheet with zero debt, the 10% cash conversion ratio and reliance on volatile mark-to-market gains to fund $16.8 million in quarterly dividends warrant a cautious approach.
HQH Growth Metrics
Abrdn Healthcare Investors (HQH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.52%
5 Years7.22%
3 Years18.45%
TTM-
Profit CAGR
10 Years-1.81%
5 Years-
3 Years6.02%
TTM717.82%
EPS CAGR
10 Years-5.42%
5 Years-
3 Years0.57%
TTM778.57%
Return on Capital
10 Years-0.38%
5 Years-0.25%
3 Years-0.17%
Last Year-0.02%
Peers Comparison
Key metrics vs top competitors for Abrdn Healthcare Investors (HQH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.00 | $1.26B | 6.20 | 4.64% | 1717.36% | 18.58% | — | |
| $20.15 | $612.72M | 6.81 | 119.34% | 129.79% | 29.8% | — | |
| $12.32 | $171.74M | 27.38 | -11.44% | 21.98% | 9.69% | — | |
| $57.91 | $4.4B | 11.29 | 10.96% | 21.44% | 29.52% | — | |
| $366.44 | $197.76B | 25.75 | 9.92% | 20.95% | 89.41% | — | |
| $129.61 | $160.92B | 19.12 | 2.39% | 30.99% | 42.33% | — |
Compare HQH vs Peers
Abrdn Healthcare Investors (HQH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HQH SEC Filings & Documents
Abrdn Healthcare Investors (HQH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HQH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HQH Frequently Asked Questions
Abrdn Healthcare Investors (HQH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Abrdn Healthcare Investors's revenue?
Abrdn Healthcare Investors (HQH) reported $21.1M in revenue for fiscal year 2024.
How fast is Abrdn Healthcare Investors growing?
Abrdn Healthcare Investors (HQH) grew revenue by 4.6% over the past year. Growth has been modest.
Is HQH profitable?
Yes, Abrdn Healthcare Investors (HQH) is profitable, generating $241.3M in net income for fiscal year 2024 (1717.4% net margin).
Dividend & Returns
What is HQH's return on equity?
Abrdn Healthcare Investors (HQH) has a return on equity (ROE) of 18.6%. This is reasonable for most industries.
What is Abrdn Healthcare Investors's free cash flow?
Abrdn Healthcare Investors (HQH) generated $8.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.